PHAR: Pharming Price to Sales
Pharming Group N.V. relies on patent protection and sales of treatments for hereditary angioedema, although the company is currently successfully reducing its dependence on a single product through new immune drugs. The company's rolling P/S visualizes this transformation, with the indicator reaching 2.40. Strategic alliances with research centers and the licensing of therapies are accelerating the global market entry of orphan drugs.
Metric breakdowns and analytics for Pharming (PHAR)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- earnings and valuation multiples indicators:
PHAR - Net Profit|Projected Net Profit Pharming Group N.V.|PHAR - Price to Earnings Ratio|Future Price to Earnings Multiple Pharming Group NV|PHAR - PEG Multiple|Enterprise Value to EBITDA Multiple Pharming|PHAR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Pharming Group|PHAR - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months pharming.com|PHAR - Net earnings per share growth this year|Earnings growth forecast for next year Pharming Group N.V.
- issuer revenue and sales details:
Fundamental company analysis:PHAR (pharming.com)
The stability of Pharming Group N.V. (PHAR) is based on the lifelong demand from insurers for high-cost drugs used to treat rare pathologies. The P/S ratio compares market capitalization to annual revenue, allowing the price-to-sales trend to determine the extent of the asset's overvaluation and assess the long-term effectiveness of monetizing patented biological developments.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio PTGX|IMVT: P/S Multiple|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BioCryst BCRX|VERA - Market Cap to Revenue|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TRML|PGEN (Precigen, Inc.) - P/S Multiple|NKTR - Price-to-Revenue Multiple|Market Cap to Revenue UPB (Upstream Bio)|ZBIO (Zenas Bio) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMNM (Immunome Corp)|Price-to-Revenue Multiple Gossamer Bio Corp.|KALV - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|Pieris Pharmaceuticals, Inc. (PVLA) - Price-to-Revenue Ratio|Price to Sales Savara Inc (SVRA)|Market Cap to Revenue RIGL|P/S Multiple AnaptysBio Inc.|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN: Price-to-Sales Ratio|RAPT Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio JBIO|ACRS - Price-to-Revenue Ratio|KYTX (Kyverna Therapeutics, Inc) - Market Cap to Revenue Ratio|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|CABA - Price-to-Revenue Coefficient|Market Cap to Revenue VTYX|Price-to-Revenue Ratio THTX|Market Cap to Revenue AVTX (Avalo Therapeutics Inc.)|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|Price-to-Revenue Ratio Agenus AGEN|CLYM (climbbio.com) - Price-to-Sales Ratio|Zura Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Labs Inc|EQ: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX: Price-to-Sales Ratio|P/S Multiple ATRA (Atara Bio)|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Price-to-Sales Ratio REVB (Revelation Biosciences Corp)|INDP (Indaptus Therapeutics) - P/S Multiple|SCNI: Market Capitalization-to-Revenue Ratio|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|Market Capitalization-to-Revenue Ratio HOOK|IGMS - Price-to-Revenue Ratio|iteostherapeutics.com (ITOS) - Market Cap to Revenue|OCEA: P/S Multiple|TCBP - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Third Harmonic Bio, Inc
